Trial Profile
Dose-intensified rechallenge with temozolomide, one week on one week off versus three weeks on one week off in patients with progressive or recurrent glioblastoma: a prospective, multicentre, multinational, randomised, parallel-group, open, phase II trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms DIRECTOR
- 31 May 2020 Results of pooled analysis from DIRECTOR and ARTE studies assessing association of CD4+ T-cell depletion under temozolomide with inferior survival presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2013 105 of 166 patients have been enrolled (53 patients in Arm A and 52 patients in Arm B) before the enrollment was prematurely stopped on 30 June 2012. The database will be closed on 30 June 2013, according to the abstract presented at ASCO